Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis.

Systemic sclerosis is characterized by fibrosis and systemic autoimmunity; however, roles of autoantibodies in the development of fibrosis remain unknown in systemic sclerosis. The net accumulation of extracellular matrix is dependent on the balance between the synthesis and degradation of extracellular matrix components, the latter process regulated by matrix metalloproteinases. Matrix metalloproteinase-1 (interstitial collagenase-1) can initiate degradation of collagen types I-III that are major extracellular matrix constituents in affected skin of systemic sclerosis. In this study, we tested the hypothesis that systemic autoimmunity in systemic sclerosis induced anti-matrix metalloproteinase-1 autoantibodies that inhibited matrix metallo-proteinase-1 activity, resulting in collagen accumulation. Enzyme-linked immunosorbent assay using human recombinant matrix metalloproteinase-1 revealed that IgG anti-matrix metalloproteinase-1 autoantibody levels were significantly elevated in sera from patients with systemic sclerosis, but not patients with active systemic lupus erythematosus or dermatomyositis, relative to normal controls. IgG anti-matrix metalloproteinase-1 autoantibody levels were significantly higher in patients with diffuse cutaneous systemic sclerosis than those found in patients with limited cutaneous systemic sclerosis. Furthermore, IgG anti-matrix metalloproteinase-1 antibody levels significantly correlated with the extent of fibrosis in the skin, lung, and renal blood vessels. The presence of IgG anti-matrix metalloproteinase-1 autoantibody in sera from systemic sclerosis patients was confirmed by immunoblotting analysis. Remarkably, IgG anti-matrix metalloproteinase-1 autoantibody in sera from systemic sclerosis patients inhibited matrix metalloproteinase-1 collagenase activity. Collectively, the results of this study suggest that anti-matrix metalloproteinase-1 autoantibody contributes to the development of fibrosis by inhibiting matrix metalloproteinase-1 collagenase activity and reducing the extracellular matrix turnover and suggest that the presence of anti-matrix metalloproteinase-1 autoantibody in systemic sclerosis is the link between systemic autoimmunity and fibrosis.

[1]  齊藤 恵里子.  CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse , 2003 .

[2]  C. Benoist,et al.  How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease , 2002, Nature Immunology.

[3]  M. Hasegawa,et al.  Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. , 2001, Rheumatology.

[4]  G. Murphy,et al.  Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls. , 2001, Annals of the rheumatic diseases.

[5]  J. Reveille,et al.  Lack of association of a functionally relevant single nucleotide polymorphism of matrix metalloproteinase-1 promoter with systemic sclerosis (scleroderma) , 2001, Genes and Immunity.

[6]  M. Hasegawa,et al.  Renal vascular damage in Japanese patients with systemic sclerosis. , 2001, Rheumatology.

[7]  T. Tedder,et al.  Quantitative Genetic Variation in CD19 Expression Correlates with Autoimmunity1 , 2000, The Journal of Immunology.

[8]  S. Sato.  Abnormalities of adhesion molecules and chemokines in scleroderma. , 1999, Current opinion in rheumatology.

[9]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. , 1999, The Journal of clinical investigation.

[10]  K. Rajewsky,et al.  From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. , 1999, Immunity.

[11]  V. Kähäri,et al.  Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts. , 1998, The Journal of investigative dermatology.

[12]  D. Gomez,et al.  Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. , 1997, European journal of cell biology.

[13]  V. Kähäri,et al.  Matrix metalloproteinases in skin , 1997, Experimental dermatology.

[14]  H. Shinkai,et al.  Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis , 1997, Archives of Dermatological Research.

[15]  M. Furue,et al.  Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts. , 1997, The Journal of investigative dermatology.

[16]  S. Jimenez,et al.  Pathogenesis of scleroderma. Collagen. , 1996, Rheumatic diseases clinics of North America.

[17]  Y. Okano,et al.  Antinuclear antibody in systemic sclerosis (scleroderma). , 1996, Rheumatic diseases clinics of North America.

[18]  R. Silver.  CLINICAL PROBLEMS: The Lungs , 1996 .

[19]  M. Fujimoto,et al.  Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis. , 1995, Journal of the American Academy of Dermatology.

[20]  R. Jaenisch,et al.  A targeted mutation at the known collagenase cleavage site in mouse type I collagen impairs tissue remodeling , 1995, The Journal of cell biology.

[21]  B. Chua,et al.  Myofibroblasts from Scleroderma Skin Synthesize Elevated Levels of Collagen and Tissue Inhibitor of Metalloproteinase (TIMP-1) with Two Forms of TIMP-1 (*) , 1995, The Journal of Biological Chemistry.

[22]  George Bou-Gharios,et al.  Excess matrix accumulation in scleroderma is caused partly by differential regulation of stromelysin and TIMP-1 synthesis. , 1994, Clinica chimica acta; international journal of clinical chemistry.

[23]  K. Takeda,et al.  Decreased collagenase expression in cultured systemic sclerosis fibroblasts. , 1994, The Journal of investigative dermatology.

[24]  H. Ihn,et al.  Antihistone antibodies in systemic sclerosis. Association with pulmonary fibrosis. , 1994, Arthritis and rheumatism.

[25]  A. Silman,et al.  Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. , 1993, The Journal of rheumatology.

[26]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[27]  L. True,et al.  Unusual causes of increased vascular impedance in renal transplants: duplex Doppler evaluation. , 1988, Radiology.

[28]  T. Medsger,et al.  Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. , 1988, Arthritis and rheumatism.

[29]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[30]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[31]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[32]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[33]  A. Bailey,et al.  Characterization of dermal collagen in systemic sclerosis , 1979, The British journal of dermatology.

[34]  A. Bohan,et al.  Polymyositis and dermatomyositis (second of two parts). , 1975, The New England journal of medicine.

[35]  A. Bohan,et al.  Polymyositis and dermatomyositis (second of two parts). , 1975 .

[36]  E. Leroy,et al.  Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. , 1974, The Journal of clinical investigation.

[37]  M. Fujimoto,et al.  Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis. , 2000, Journal of the American Academy of Dermatology.